News
Updates on activities and accomplishments at AYOXXA
As a young and dynamic company determined to anticipate and respond to customer needs, we continue to achieve milestones, bring novel products to market, expand our partnerships, and explore use of our LUNARIS™ technology in new research areas. Follow these developments here.
Webinars
Webinar on Demand
Enabling cell therapy research with multiplex biomarker analysis
If you’re looking for a sensitive, robust, and precise multiplex biomarker quantification platform that enables your cell therapy research, this webinar is for you.
Read moreCoronavirus Update
Coronavirus Update
DOING OUR PART IN THE FIGHT
Our commitment is to advance science and we have transformed that pledge into action: support for COVID-19 research with the complete LUNARIS™ platform at a special price.
Read more
Coronavirus Update
EVERY SAMPLE COUNTS. EVERY INSIGHT COUNTS.
Knowledge is our weapon against Coronavirus – and insights into how SARS-CoV-2 works is what AYOXXA can offer the scientific community.
Read more
Coronavirus Update
OUR COMMITMENT: BACKING UP THE FRONTLINE
Scientists are at the frontline in the fight against coronavirus. With thousands of other unsung heroes worldwide, they keep our healthcare and infrastructure at the ready. To you: thank you! We are humbled by your dedication and grateful for your service.
Read moreConferences
Meet AYOXXA
AYOXXA @ Cytokines 2022 Hybrid Meeting
After two years meeting in the virtual space, AYOXXA’s representatives look forward to catching up with leading scientist performing translational research related to cytokine biology.
Read more
Meet AYOXXA
AYOXXA @ DGfI / ÖGAI Joint Meeting 2022
We from AYOXXA look forward to meeting with researchers focusing on the immune system and its role in various diseases! We offer the LUNARIS™ Multiplex Technology to support your basic and clinical research to uncover biomarker signatures and their role in the immune response. Ask us about our LUNARIS™ Cytokine and NEW Complement & Inflammasome Kits!
Read more
Meet AYOXXA
AYOXXA @ SSAI & ICHS Joint Meeting 2022
Dr. Bettina Müller is delighted to introduce the LUNARIS™ Multiplex Technology to a high calibre network of scientists from the Swiss Society for Allergology and Immunology (SSAI) and the International Immunocompromised Host Society (ICHS). The joint meeting will take place at the Congress Center Basel.
Read more
Meet AYOXXA
AYOXXA @ ARVO 2022
We are thrilled to join a lively reunion of world’s leading experts for eye and vision research aiming to “Accelerate Discovery through Team Science”!
Read more
Meet AYOXXA
AYOXXA @ Cytokines 2021
After last year’s great success, Cytokines 2021 will be held virtually again. AYOXXA is thrilled to attend: the virtual platform is excellent, and the program is a stellar list of presentations and discussions about sensing and interpreting cytokine & interferon cues.
Read more
Meet AYOXXA
AYOXXA @ Cytokines 2020
In step with other scientific meetings, Cytokines 2020 will be held virtually. AYOXXA is thrilled to attend: the virtual platform is excellent, and the program is a stellar list of presentations and discussions about systems-level cytokine action.
Read morePress Reviews
Press Review
Multi-cytokine profiles inform treatment decisions
Proteomics is an indispensable tool to elucidate disease etiology. Understanding the molecular background of a disease enables the development of more effective drugs and precise, reliable diagnostics.
Read more
Press Review
June Cover Story: Deep Tech
With AYOXXA cited as one of "the hottest Southeast Asian startups in Biotech", this article is telling the story of co-founders Andreas Schmidt & Dieter Trau: From first conceptual ideas to groundbreaking technology platform and growing AYOXXA into a young, innovative Biotech company.
Read more
Press Review
Translational proteomics at clinical scale
Proteomics is an indispensable methodology for advancing our understanding of disease etiology and the process of drug development, particularly in the post-genome era. Today, researchers often analyze entire protein networks and translate the knowledge generated from basic research into powerful clinical approaches in medical sciences. To fully explore this complex biology, enabling tools and technologies are vital.
Read more
Press Review
Why did you name your company AYOXXA Biosystems?
Interview with Wolfgang Kintzel (Co-CEO) and Dr. Markus Zumbansen (CTO), both from AYOXXA Biosystems. Article published in German language.
Read more
Press Review
Sandwich on beads
Cologne-based AYOXXA Biosystems counts on the simultaneous quantification of Cytokines and other biomarkers, captured by antibody-coated microbeads. Company profile authored by Sigrid März, Freelancer for Laborjournal. Read full-text company profile in German language.
Read more
Press Review
AYOXXA launches LUNARIS Protein Analysis System in Asia
Founded in 2010 as a spin-off of the National University of Singapore, AYOXXA Biosystems is one of the success stories of Singapore’s Biotech start-up community. It has since grown into a global biotech company headquartered in Cologne, Germany, and it remains focused on the development and commercialization of its proprietary technology for advanced protein analysis, LUNARIS™. AYOXXA Living Health Technologies Pte.
Read morePress Releases
Press Release
AYOXXA receives fresh capital for commercial growth
AYOXXA Biosystems GmbH, active in the development of multiplex protein analysis assays for drug discovery and translational research, today announced the successful closing of a financing round which will provide runway for the coming 3 - 5 years.
Read more
Press Release
AYOXXA launches the new LUNARIS™ Reader designed to facilitate translational research in academic and industrial laboratories
AYOXXA Biosystems GmbH, an international biotechnology company offering a range of products and services which enable advances in translational proteomics, today announces the launch of their next generation LUNARIS™ Reader.
Read more
Press Release
AYOXXA launches LUNARIS™ Human and Mouse Chemokine Kits to explore chemokine signaling
AYOXXA Biosystems GmbH, an international biotechnology company offering a range of products and services which enable advances in translational proteomics, today announces the expansion of its catalogue of kits for fully scalable multiplex protein analysis with the introduction of LUNARIS™ Chemokine Kits for exploration of human (Human 11-Plex) and murine (Mouse-12-Plex) chemokine signaling pathways.
Read more
Press Release
AYOXXA signs research agreement in the field of ophthalmology with one of the leading pharmaceutical companies
AYOXXA Biosystems GmbH, an international biotechnology company offering a range of products and services which enable advances in translational proteomics, today announced that it has signed a research agreement with one of the leading pharmaceutical companies for the development of a series of low volume, high sensitivity multiplex protein assays intend to validate protein biomarkers in the field of ophthalmology.
Read more
Press Release
AYOXXA launches LUNARIS™ Human & Mouse 6-Plex T Cell Characterization Kits to elucidate T cell differentiation
AYOXXA Biosystems GmbH, an international biotechnology company offering a range of products and services which enable advances in translational proteomics, today announced the expansion of its catalogue of kits for fully scalable multiplex protein analysis with the introduction of LUNARISTM Human & Mouse 6-Plex T Cell Characterization Kits.
Read more
Press Release
AYOXXA launches LUNARIS™ Human 12-Plex Th17 Kit expanding its portfolio for fully scalable biomarker analysis
AYOXXA Biosystems GmbH, an international biotechnology company offering a range of products and services which enable advances in translational proteomics, today announced the expansion of its catalogue of kits for fully scalable multiplex protein analysis with the introduction of LUNARISTM Human 12-Plex Th17 Kit for the quantitative validation of soluble pro-inflammatory T helper 17 (Th17) cell-related markers.
Read more